Connor Clark & Lunn Investment Management Ltd. Acquires 125,532 Shares of Zai Lab Limited (NASDAQ:ZLAB)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 26.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 604,153 shares of the company's stock after purchasing an additional 125,532 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.61% of Zai Lab worth $14,584,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of ZLAB. BNP Paribas Financial Markets raised its holdings in shares of Zai Lab by 51.2% during the 1st quarter. BNP Paribas Financial Markets now owns 2,671 shares of the company's stock valued at $43,000 after purchasing an additional 904 shares in the last quarter. Capital International Inc. CA raised its holdings in shares of Zai Lab by 6.7% during the 1st quarter. Capital International Inc. CA now owns 92,108 shares of the company's stock valued at $1,476,000 after purchasing an additional 5,815 shares in the last quarter. Capital World Investors raised its holdings in shares of Zai Lab by 8.9% during the 1st quarter. Capital World Investors now owns 5,684,180 shares of the company's stock valued at $91,061,000 after purchasing an additional 465,337 shares in the last quarter. Bamco Inc. NY raised its holdings in shares of Zai Lab by 7.3% during the 1st quarter. Bamco Inc. NY now owns 1,599,865 shares of the company's stock valued at $25,630,000 after purchasing an additional 108,991 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in Zai Lab by 9.6% in the 1st quarter. Janus Henderson Group PLC now owns 4,428,011 shares of the company's stock valued at $70,924,000 after buying an additional 387,729 shares during the last quarter. Institutional investors own 41.65% of the company's stock.

Wall Street Analysts Forecast Growth

ZLAB has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on shares of Zai Lab from $38.00 to $44.00 and gave the company an "overweight" rating in a research note on Monday, October 21st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a research note on Friday, October 25th.

Zai Lab Stock Down 1.2 %

NASDAQ ZLAB traded down $0.31 during midday trading on Thursday, hitting $25.92. The company had a trading volume of 77,385 shares, compared to its average volume of 702,734. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -9.47 and a beta of 1.04. The firm has a fifty day simple moving average of $26.28 and a two-hundred day simple moving average of $21.26. Zai Lab Limited has a fifty-two week low of $13.48 and a fifty-two week high of $36.60.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.